270 related articles for article (PubMed ID: 35943588)
1. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
Leleu X; Martin T; Weisel K; Schjesvold F; Iida S; Malavasi F; Manier S; Chang-Ki Min ; Ocio EM; Pawlyn C; Perrot A; Quach H; Richter J; Spicka I; Yong K; Richardson PG
Ann Hematol; 2022 Oct; 101(10):2123-2137. PubMed ID: 35943588
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
Shah B; Gray J; Abraham I; Chang M
J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
4. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ; Usmani SZ
Front Immunol; 2018; 9():2134. PubMed ID: 30294326
[TBL] [Abstract][Full Text] [Related]
5. CD38 targeted treatment for multiple myeloma.
Jelínek T; Mihályová J; Hájek R
Vnitr Lek; 2018; 64(10):939-948. PubMed ID: 30590941
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
Chami B; Okuda M; Moayeri M; Pirenne F; Hidaka Y; Nambiar A; Song Z; Bedel O; Zhang B; Hopke J; Deng G; Zhu C; Macé S; Chiron M; Adrian F; Fukao T; Basile FG; Martin T
Transfusion; 2022 Nov; 62(11):2334-2348. PubMed ID: 36239134
[TBL] [Abstract][Full Text] [Related]
7. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
[TBL] [Abstract][Full Text] [Related]
8. Isatuximab for the treatment of multiple myeloma.
Goldsmith SR; Liu L; Covut F
Drugs Today (Barc); 2021 Nov; 57(11):665-675. PubMed ID: 34821880
[TBL] [Abstract][Full Text] [Related]
9. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
Shen F; Shen W
Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
[TBL] [Abstract][Full Text] [Related]
10. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
15. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
[TBL] [Abstract][Full Text] [Related]
16. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
Plesner T; van de Donk N; Richardson PG
Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
[TBL] [Abstract][Full Text] [Related]
17. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Richardson PG; Beksaç M; Špička I; Mikhael J
Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
[TBL] [Abstract][Full Text] [Related]
18. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
19. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.
Perez de Acha O; Reiman L; Jayabalan DS; Walker ZJ; Bosma G; Keller AL; Parzych SE; Abbott D; Idler BM; Ribadeneyra D; Niesvizky R; Forsberg PA; Mark TM; Sherbenou DW
Blood Adv; 2023 Nov; 7(21):6430-6440. PubMed ID: 37648670
[TBL] [Abstract][Full Text] [Related]
20. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
